Development and evaluation of an 18F-labeled nanobody to target SARS-CoV-2's spike protein
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Development and evaluation of an 18F-labeled nanobody to target SARS-CoV-2's spike protein. / Lopes van den Broek, Sara; García-Vázquez, Rocío; Andersen, Ida Vang; Valenzuela-Nieto, Guillermo; Shalgunov, Vladimir; Battisti, Umberto M.; Schwefel, David; Modhiran, Naphak; Kramer, Vasko; Cheuquemilla, Yorka; Jara, Ronald; Salinas-Varas, Constanza; Amarilla, Alberto A.; Watterson, Daniel; Rojas-Fernandez, Alejandro; Herth, Matthias M.
In: Frontiers in Nuclear Medicine, Vol. 2, 1033697, 2022.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Development and evaluation of an 18F-labeled nanobody to target SARS-CoV-2's spike protein
AU - Lopes van den Broek, Sara
AU - García-Vázquez, Rocío
AU - Andersen, Ida Vang
AU - Valenzuela-Nieto, Guillermo
AU - Shalgunov, Vladimir
AU - Battisti, Umberto M.
AU - Schwefel, David
AU - Modhiran, Naphak
AU - Kramer, Vasko
AU - Cheuquemilla, Yorka
AU - Jara, Ronald
AU - Salinas-Varas, Constanza
AU - Amarilla, Alberto A.
AU - Watterson, Daniel
AU - Rojas-Fernandez, Alejandro
AU - Herth, Matthias M.
N1 - Funding Information: This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813528. Additionally, this project has received funding from the European Union's EU Framework Programme for Research and Innovation Horizon 2020, under grant agreement no. 668532. The Lundbeck Foundation (grant no. R303-2018-3567) and the Research Council for Independent Research (grant agreement no. 8022-00187B) are further acknowledged. DS was supported by the German Research Foundation (DFG) Emmy Noether Programme (SCHW1851/1-1) and by an EMBO Advanced grant (aALTF-1650). The Chilean platform for the generation and characterization of Camelid Nanobodies to A.R.F is funded by FONDECYT No. 1200427; the regional Council of the “Los Rios region” projects FICR19–20, FICR21–01; FICR20–49 to R.J; the Bio & Medical Technology Development Program of the National Research Foundation (NRF) of the Korean government (MSIT) (NRF-2020M3A9H5112395); the ANID-MPG MPG190011 and ANID-STINT CS2018–7952 grants. Publisher Copyright: 2022 Lopes van den Broek, García-Vázquez, Andersen, Valenzuela-Nieto, Shalgunov, Battisti, Schwefel, Modhiran, Kramer, Cheuquemilla, Jara, Salinas-Varas, Amarilla, Watterson, Rojas-Fernandez and Herth.
PY - 2022
Y1 - 2022
N2 - COVID-19, caused by the SARS-CoV-2 virus, has become a global pandemic that is still present after more than two years. COVID-19 is mainly known as a respiratory disease that can cause long-term consequences referred to as long COVID. Molecular imaging of SARS-CoV-2 in COVID-19 patients would be a powerful tool for studying the pathological mechanisms and viral load in different organs, providing insights into the disease and the origin of long-term consequences and assessing the effectiveness of potential COVID-19 treatments. Current diagnostic methods used in the clinic do not allow direct imaging of SARS-CoV-2. In this work, a nanobody (NB) – a small, engineered protein derived from alpacas – and an Fc-fused NB which selectively target the SARS-CoV-2 Spike protein were developed as imaging agents for positron emission tomography (PET). We used the tetrazine ligation to 18F-label the NB under mild conditions once the NBs were successfully modified with trans-cyclooctenes (TCOs). We confirmed binding to the Spike protein by SDS-PAGE. Dynamic PET scans in rats showed excretion through the liver for both constructs. Future work will evaluate in vivo binding to the Spike protein with our radioligands.
AB - COVID-19, caused by the SARS-CoV-2 virus, has become a global pandemic that is still present after more than two years. COVID-19 is mainly known as a respiratory disease that can cause long-term consequences referred to as long COVID. Molecular imaging of SARS-CoV-2 in COVID-19 patients would be a powerful tool for studying the pathological mechanisms and viral load in different organs, providing insights into the disease and the origin of long-term consequences and assessing the effectiveness of potential COVID-19 treatments. Current diagnostic methods used in the clinic do not allow direct imaging of SARS-CoV-2. In this work, a nanobody (NB) – a small, engineered protein derived from alpacas – and an Fc-fused NB which selectively target the SARS-CoV-2 Spike protein were developed as imaging agents for positron emission tomography (PET). We used the tetrazine ligation to 18F-label the NB under mild conditions once the NBs were successfully modified with trans-cyclooctenes (TCOs). We confirmed binding to the Spike protein by SDS-PAGE. Dynamic PET scans in rats showed excretion through the liver for both constructs. Future work will evaluate in vivo binding to the Spike protein with our radioligands.
KW - alpaca
KW - biodistribution
KW - COVID-19
KW - nanobodies
KW - PET
KW - SARS-CoV-2
KW - tetrazine ligation
U2 - 10.3389/fnume.2022.1033697
DO - 10.3389/fnume.2022.1033697
M3 - Journal article
AN - SCOPUS:85183642532
VL - 2
JO - Frontiers in Nuclear Medicine
JF - Frontiers in Nuclear Medicine
SN - 2673-8880
M1 - 1033697
ER -
ID: 387556659